Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-042043
Filing Date
2025-05-12
Accepted
2025-05-12 16:15:45
Documents
61
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0239115-10q_hoth.htm   iXBRL 10-Q 599897
2 CERTIFICATION ea023911501ex31-1_hoth.htm EX-31.1 11705
3 CERTIFICATION ea023911501ex31-2_hoth.htm EX-31.2 11527
4 CERTIFICATION ea023911501ex32-1_hoth.htm EX-32.1 3817
5 CERTIFICATION ea023911501ex32-2_hoth.htm EX-32.2 3862
  Complete submission text file 0001213900-25-042043.txt   4619399

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE hoth-20250331.xsd EX-101.SCH 44657
7 XBRL CALCULATION FILE hoth-20250331_cal.xml EX-101.CAL 26779
8 XBRL DEFINITION FILE hoth-20250331_def.xml EX-101.DEF 229009
9 XBRL LABEL FILE hoth-20250331_lab.xml EX-101.LAB 408768
10 XBRL PRESENTATION FILE hoth-20250331_pre.xml EX-101.PRE 244688
63 EXTRACTED XBRL INSTANCE DOCUMENT ea0239115-10q_hoth_htm.xml XML 472764
Mailing Address 1177 AVENUE OF THE AMERICAS 5TH FLOOR SUITE 5066 NEW YORK NY 10036
Business Address 1177 AVENUE OF THE AMERICAS 5TH FLOOR SUITE 5066 NEW YORK NY 10036 (646)756-2997
Hoth Therapeutics, Inc. (Filer) CIK: 0001711786 (see all company filings)

EIN.: 821553794 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38803 | Film No.: 25935069
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)